Medication-Assisted Treatment (MAT)
What is medication-assisted treatment?
- Medication-assisted treatment (MAT) is the use of FDA-approved medications, along with appropriate counseling and behavioral therapy, to treat substance use disorder and sustain recovery.
Physician training and education on MAT
- For a physician to be eligible to prescribe or dispense buprenorphine for the purpose of MAT, he or she must qualify, apply for a physician waiver, and complete an eight-hour buprenorphine waiver training.
- Residential Substance Abuse Treatment (RSAT) Training Tool: Medication-assisted treatment (MAT) for offender populations provides evidence-based information on the application and effectiveness of MAT among the offender population during incarceration and as they are released and re-enter the community.
- The Addiction Technology Transfer center (ATTC) provides online training designed to enhance professionals’ knowledge and skills related to MAT and increasing the use of MAT.
- Substance Abuse and Mental Health Services Administration’s (SAMHSA) Medication-Assisted Treatment of Opioid Use Disorder Pocket Guide provides physicians with information on approved medications, screening and assessment tools, and best practices for patient care.
- Webinars, workshops and summits provided by SAMHSA.
- Webinars and educational videos provided by Providers Clinical Support System.
- Publications and research provided by SAMHSA.
Visit the SAMHSA website or call SAMHSA at 1-866-BUP-CSAT (1-866-287-2728) for more information about physician waiver qualifications, treatment training in your area or to obtain a waiver.
Opioid ECHO Project
- The Opioid ECHO project is a free partnership between local primary care providers and a team of specialists from Indiana University (IU). It aims to improve the treatment of opioid use disorder in rural and underserved areas by educating primary care clinicians through virtual video-conferencing to provide specialty care services.
- IU will conduct three separate ECHO clinics for the following disciplines: prescribers, behavioral health specialists, and community health workers/peer recovery workers.
- Each clinic has a curriculum that is 12 sessions long. After the curriculum is completed, the clinic will restart at the beginning with a new cohort of participants.
- Visit the Opioid ECHO Project website if you are interested in joining.
Additional MAT Resources
- Physicians must confirm that that they will not prescribe buprenorphine to more than 30 patients during the first year of obtaining their buprenorphine waiver. Following the first year, physicians can apply for approval to treat up to 100 patients. Learn more on applying to increase patient limits after the first year.
- Unlike physicians, pharmacists do not need a buprenorphine waiver to dispense buprenorphine. No additional credentials are required for a pharmacist to dispense a schedule III substance, such as buprenorphine. However, when the medication has been prescribed they are required to go to the Buprenorphine Pharmacy Lookup and verify the prescribing physician’s buprenorphine certification. Learn more about verifying physician waivers for pharmacists.
- As of 2017, there are 13 opioid treatment programs (OTPs) in the state of Indiana (demonstrated by the dark blue pins on the map). Additionally, five new OTPs are scheduled to open by the end of 2018, and are demonstrated by the light blue pins on the map. To find an OTP, visit https://www.in.gov/recovery/.
Page last updated 01/16/2020